Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme

Inclusion Criteria: * Patients must have pathologically confirmed (histology or cytology), resectable or non resectable, glioblastoma multiforme with a size \< 5 cm on MRI if non resectable * Patients must be at least 7 days but no more than 2 months since surgery or biopsy. * Patients must have an ECOG Performance Status ≤ 2. * Patients must be aged 18 * Patient has signed the informed consent form Exclusion Criteria: * Patients with unresectable glioblastoma with a size \>5 cm on MRI * Patients with clinically apparent leptomeningeal metastases * Patients with uncontrolled seizures despite standard anticonvulsant therapy * Any prior systemic treatment (chemotherapy, immunotherapy, hormonal therapy) for glioblastoma multiforme * Significantly abnormal haematological status as judged by: Absolute neutrophil count (ANC) \< 1500/mm3 (1.5\*109/l) Platelet count \<100,000/mm3 (100\*109/l) * Serum bilirubin \>2 mg/dl (\>34 mmol/l) or Transaminase \>2.5x the upper limit of institutional normal or Creatinine \>1.5 mg/dl (\>132 mmol/l) * Inability to co-operate with the treatment protocol * Patients who cannot undergo imaging evaluations * Participation in an investigational drug trial in the 30 days prior to selection * Pregnant or nursing mothers. (Female patients of childbearing potential must use adequate contraception.) * Any malignancy within the past five years. Exceptions are: superficial basal cell carcinoma or non-metastatic squamous cell cancer of the skin, cervix can…